<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Isoniazid for preventing tuberculosis in HIV‐infected children - Zunza, M - 2017 | Cochrane Library</title> <meta content="Isoniazid for preventing tuberculosis in HIV‐infected children - Zunza, M - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006418.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Isoniazid for preventing tuberculosis in HIV‐infected children - Zunza, M - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006418.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006418.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Isoniazid for preventing tuberculosis in HIV‐infected children" name="citation_title"/> <meta content="Moleen Zunza" name="citation_author"/> <meta content="Stellenbosch University" name="citation_author_institution"/> <meta content="moleenz@sun.ac.za" name="citation_author_email"/> <meta content="Diane M Gray" name="citation_author"/> <meta content="Red Cross War Memorial Children's Hospital and University of Cape Town" name="citation_author_institution"/> <meta content="Taryn Young" name="citation_author"/> <meta content="Mark Cotton" name="citation_author"/> <meta content="Tygerberg Children's Hospital" name="citation_author_institution"/> <meta content="Heather J Zar" name="citation_author"/> <meta content="Red Cross Children's Hospital and MRC Unit on Child and Adolescent Health, University of Cape Town" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD006418.pub3" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/08/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006418.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006418.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006418.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="AIDS-Related Opportunistic Infections [mortality, *prevention &amp; control]; Anti-HIV Agents [therapeutic use]; Antitubercular Agents [adverse effects, *therapeutic use]; HIV Infections [drug therapy, *mortality]; Incidence; Isoniazid [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Trimethoprim, Sulfamethoxazole Drug Combination [adverse effects, therapeutic use]; Tuberculosis, Multidrug-Resistant [epidemiology]; Tuberculosis, Pulmonary [drug therapy, *mortality, *prevention &amp; control]" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006418.pub3&amp;doi=10.1002/14651858.CD006418.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006418.pub3&amp;doi=10.1002/14651858.CD006418.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006418.pub3&amp;doi=10.1002/14651858.CD006418.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006418.pub3&amp;doi=10.1002/14651858.CD006418.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006418.pub3&amp;doi=10.1002/14651858.CD006418.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006418.pub3&amp;doi=10.1002/14651858.CD006418.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006418.pub3&amp;doi=10.1002/14651858.CD006418.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006418.pub3&amp;doi=10.1002/14651858.CD006418.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006418.pub3&amp;doi=10.1002/14651858.CD006418.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006418.pub3&amp;doi=10.1002/14651858.CD006418.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006418.pub3&amp;doi=10.1002/14651858.CD006418.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006418.pub3&amp;doi=10.1002/14651858.CD006418.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006418.pub3&amp;doi=10.1002/14651858.CD006418.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006418.pub3&amp;doi=10.1002/14651858.CD006418.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006418.pub3&amp;doi=10.1002/14651858.CD006418.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006418.pub3&amp;doi=10.1002/14651858.CD006418.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006418.pub3&amp;doi=10.1002/14651858.CD006418.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006418.pub3&amp;doi=10.1002/14651858.CD006418.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006418.pub3&amp;doi=10.1002/14651858.CD006418.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006418.pub3&amp;doi=10.1002/14651858.CD006418.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006418.pub3&amp;doi=10.1002/14651858.CD006418.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006418.pub3&amp;doi=10.1002/14651858.CD006418.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006418.pub3&amp;doi=10.1002/14651858.CD006418.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="QO4KtYGW";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006418\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006418\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006418\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006418\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD006418.pub3",title:"Isoniazid for preventing tuberculosis in HIV\\u2010infected children",firstPublishedDate:"Aug 29, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Infectious Diseases Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QO4KtYGW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006418.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006418.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006418.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006418.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006418.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006418.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006418.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006418.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006418.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006418.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4565 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006418.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/full#CD006418-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/full#CD006418-sec-0084"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/full#CD006418-sec-0023"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/full#CD006418-sec-0024"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/full#CD006418-sec-0029"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/full#CD006418-sec-0030"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/full#CD006418-sec-0052"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/full#CD006418-sec-0078"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/appendices#CD006418-sec-0089"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/table_n/CD006418StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/table_n/CD006418StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Isoniazid for preventing tuberculosis in HIV‐infected children</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/information#CD006418-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Moleen Zunza</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/information#CD006418-cr-0003">Diane M Gray</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/information#CD006418-cr-0004">Taryn Young</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/information#CD006418-cr-0005">Mark Cotton</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006418.pub3/information#CD006418-cr-0006">Heather J Zar</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/information/en#CD006418-sec-0096">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 August 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006418.pub3">https://doi.org/10.1002/14651858.CD006418.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006418-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006418-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006418-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006418-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006418-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006418-abs-0001" lang="en"> <section id="CD006418-sec-0001"> <h3 class="title" id="CD006418-sec-0001">Background</h3> <p>Tuberculosis (TB) is an important cause of illness and death in HIV‐positive children living in areas of high TB prevalence. We know that isoniazid prophylaxis prevents TB in HIV‐negative children following TB exposure, but there is uncertainty related to its role in TB preventive treatment in HIV‐positive children. </p> </section> <section id="CD006418-sec-0002"> <h3 class="title" id="CD006418-sec-0002">Objectives</h3> <p>To summarise the effects of TB preventive treatment versus placebo in HIV‐positive children with no known TB contact on active TB, death, and reported adverse events. </p> </section> <section id="CD006418-sec-0003"> <h3 class="title" id="CD006418-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE/PubMed, Embase and two trial registers up to February 2017. </p> </section> <section id="CD006418-sec-0004"> <h3 class="title" id="CD006418-sec-0004">Selection criteria</h3> <p>We included trials of HIV‐positive children with and without known TB exposure, randomized to receive TB preventive treatment or placebo. </p> </section> <section id="CD006418-sec-0005"> <h3 class="title" id="CD006418-sec-0005">Data collection and analysis</h3> <p>Two review authors independently used the study selection criteria, assessed risk of bias, and extracted data. We assessed effects using risk, incidence rate and hazard ratios and assessed the certainty of evidence using GRADE. </p> </section> <section id="CD006418-sec-0006"> <h3 class="title" id="CD006418-sec-0006">Main results</h3> <p>We included three trials, involving 991 participants, below the age of 13 years, from South Africa and Botswana. Children were randomized to isoniazid prophylaxis or placebo, given daily or three times weekly. The median length of follow‐up ranged from 5.7 to 34 months; some were on antiretroviral therapy (ART). </p> <p>In HIV‐positive children not on ART, isoniazid prophylaxis may reduce the risk of active TB (hazard ratio (HR) 0.31, 95% confidence interval (CI) 0.11 to 0.87; 1 trial, 240 participants, <i>low certainty evidence</i> ), and death (HR 0.46, 95% CI 0.22 to 0.95; 1 trial, 240 participants, <i>low certainty evidence</i>). One trial (182 participants) reported number of children with laboratory adverse events, which was similar between the isoniazid prophylaxis and placebo groups. No clinical adverse events were reported. </p> <p>In HIV‐positive children on ART, we do not know if isoniazid prophylaxis reduces the risk of active TB (risk ratio (RR) 0.76, 95% CI 0.50 to 1.14; 3 trials, 737 participants, <i>very low certainty evidence</i> ) or death (RR 1.45, 95% CI 0.78 to 2.72; 3 trials, 737 participants, <i>very low certainty evidence</i>). Two trials (714 participants) reported number of clinical adverse events and three trials (795 participants) reported number of laboratory adverse events; for both categories, the number of adverse events were similar between the isoniazid prophylaxis and placebo groups. </p> </section> <section id="CD006418-sec-0007"> <h3 class="title" id="CD006418-sec-0007">Authors' conclusions</h3> <p>Isoniazid prophylaxis given to all children diagnosed with HIV may reduce the risk of active TB and death in HIV‐positive children not on ART in studies from Africa. For children on ART, no clear benefit was detected. . </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006418-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006418-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006418-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006418-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD006418-abs-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006418-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006418-abs-0003" lang="en"> <h3>Isoniazid prophylaxis for preventing active tuberculosis and death in HIV‐positive children </h3> <p><b>What was the aim of this review?</b> </p> <p>To summarise the effects of isoniazid prophylaxis on TB, death, and adverse effects in HIV‐positive children. </p> <p><b>Key messages</b> </p> <p>In areas of high tuberculosis endemicity, isoniazid prophylaxis prevents active TB and death in HIV‐positive children who are not on ART. </p> <p>We conducted a review to assess the effect of TB medication on active TB or death and its safety in HIV‐positive children. </p> <p><b>What was studied in the review?</b> </p> <p>TB is a common cause of severe lung disease and death in HIV‐positive children. Childhood TB is common in poor countries, especially those with a coexisting burden of HIV/AIDS disease. HIV‐positive children have a higher risk of developing TB than HIV‐negative children. Isoniazid prevents TB in HIV‐positive adults and is currently used in children who are at high risk of developing TB disease after exposure to someone with TB. However, there is limited information on the effect of isoniazid medication in reducing active TB or death if given to HIV‐positive children without known TB contact. </p> <p>We searched for studies up to 17 February 2017, and found three studies published between 2007 and 2014 that addressed the effect of isoniazid medication compared to no medication on active TB and death in 991 HIV‐positive children, below the age of 13 years. Most of the children were on antiretroviral therapy (ART) and the studies were conducted in South Africa and Botswana. The median length of follow‐up ranged from 5.7 to 34 months. </p> <p><b>What are the main results of the review?</b> </p> <p>In HIV‐positive children not taking ART, isoniazid medication reduced the number of children developing active TB by 69% (<i>low certainty evidence</i> ), and death by 54% (<i>low certainty evidence</i>). </p> <p>One trial was conducted in HIV‐positive children taking ART, and this did not detect any benefit or harm of isoniazid (<i>very low certainty evidence)</i>. </p> <p>The number of children with adverse effects were similar in children receiving isoniazid medication as the control group in both children on ART and not on ART. </p> <p><b>How up to date is the review?</b> </p> <p>The review authors searched for studies published up to February 2017.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006418-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006418-sec-0084"></div> <h3 class="title" id="CD006418-sec-0085">Implications for practice</h3> <section id="CD006418-sec-0085"> <p>Isoniazid prophylaxis may reduce active tuberculosis (TB) disease and death in HIV‐positive children not on antiretroviral therapy (ART). The WHO 2013 guidelines recommend ART for all HIV‐positive children, which has to be started soon after diagnosis (<a href="./references#CD006418-bbs2-0056" title="World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, 2013. www.who.int/hiv/pub/guidelines/arv2013/download/en/ (accessed prior to 6 June 2017). ">WHO 2013</a>). However, many children have delayed access to ART and coverage is not universal in most sub‐Saharan settings, suggesting that any child awaiting ART in a high TB prevalence area, should have isoniazid prophylaxis until the child is virally suppressed and immune reconstituted. Baseline risk of HIV‐positive children on ART, benefits and harms should be considered when making treatment decisions. </p> </section> <h3 class="title" id="CD006418-sec-0086">Implications for research</h3> <section id="CD006418-sec-0086"> <p>The risk of TB is substantially higher in HIV‐positive children on ART compared to HIV‐negative children from the same community. In <a href="./references#CD006418-bbs2-0002" title="MadhiSA , NachmanS , ViolariA , KimS , CottonMF , BobatR , et al. Primary isoniazid prophylaxis against tuberculosis in HIV‐exposed children. New England Journal of Medicine2011;365(1):21‐31. ">Madhi 2011</a>, children on ART had a higher rate of TB disease, 121 cases per 1000 child‐years than HIV‐negative children, 41 per 1000 child‐years. Adequately powered trials assessing the impact of TB preventive therapy in HIV‐positive children on ART are required. A target sample size of 848 HIV‐positive children on ART will be required to have an 80% chance of detecting a 43% relative reduction, as significant at the 5% level, in the intervention group assuming a 14% baseline risk in active TB disease outcome. Trials that assess the long‐term effects of TB prophylaxis are also needed to better assess the length of benefit in different settings. The three included trials investigated isoniazid prophylaxis versus placebo. There are no data on the efficacy of other TB preventive treatment regimens. Studies in adults included multiple‐drug combination preventive treatment (<a href="./references#CD006418-bbs2-0010" title="AkoloC , AdetifaI , ShepperdS , VolminkJ . Treatment of latent infection in HIV infected persons. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000171.pub3] ">Akolo 2010</a>). However adverse events leading to discontinuation of treatment were more common for multiple‐drug therapy, as opposed to isoniazid treatment alone (<a href="./references#CD006418-bbs2-0010" title="AkoloC , AdetifaI , ShepperdS , VolminkJ . Treatment of latent infection in HIV infected persons. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000171.pub3] ">Akolo 2010</a>). </p> <p>Although most cases of definite TB in the included studies were sensitive to isoniazid prophylaxis, long‐term data on the impact of isoniazid prophylaxis on <i>Mycobacterium tuberculosis</i> sensitivity are needed. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006418-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006418-sec-0023"></div> <div class="table" id="CD006418-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Isoniazid prophylaxis compared to placebo for HIV‐positive children not on antiretroviral therapy (ART)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Isoniazid prophylaxis compared to placebo for HIV‐positive children not on antiretroviral therapy (ART)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> HIV‐positive children not taking ART<br/> <b>Settings:</b> any setting<br/> <b>Intervention:</b> isoniazid prophylaxis daily or three times weekly<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comment</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Isoniazid prophylaxis </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active TB</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 100</p> <p>(1 to 9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.31</p> <p>(95% CI 0.11 to 0.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3,4,5</sup> </p> <p>due to serious indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Isoniazid prophylaxis may reduce active TB</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 100</p> <p>(8 per 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.46</p> <p>(95% CI 0.22 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3,4,5</sup> </p> <p>due to serious indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Isoniazid prophylaxis may reduce death</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>HR</b>: hazard ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No serious risk of bias: this trial was at low risk of selection bias, and adequately blinded study participants and personnel. However, the study was stopped early on the recommendation of the data safety monitoring board after only 277 of the planned 432 were enrolled. Not downgraded.<br/> <sup>2</sup>No serious inconsistency: a single trial.<br/> <sup>3</sup>Downgraded by 1 for serious indirectness: this single trial is from a single setting in South Africa. Broad generalization of this result to other settings is difficult given the variation in isoniazid resistance worldwide.<br/> <sup>4</sup>Downgraded by 1 for serious imprecision: there were very few events in this trial and as such the finding is fragile. The original paper reports the result using a hazard ratio and the result reached standard levels of statistical significance.<br/> <sup>5</sup>We reported the study authors' data. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006418-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Isoniazid prophylaxis compared to placebo for HIV‐positive children on antiretroviral therapy (ART)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Isoniazid prophylaxis compared to placebo for HIV‐positive children on antiretroviral therapy (ART)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> HIV‐positive children on ART<br/> <b>Settings:</b> any setting<br/> <b>Intervention:</b> isoniazid prophylaxis daily or three times weekly<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Isoniazid prophylaxis </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Active TB</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 100</b> <br/> (7 to 15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.76</b> <br/> (0.50 to 1.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>737<br/> (3 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3,4</sup> </p> <p>due to serious indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We don't know if Isoniazid prophylaxis reduce active TB</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b> <br/> (3 to 11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.45</b> </p> <p>(0.78 to 2.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>737<br/> (3 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3,5</sup> </p> <p>due to serious indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We don't know if Isoniazid prophylaxis reduce death</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No serious risk of bias: trials were at low risk of selection bias. Both studies adequately blinded study participants and personnel.<br/> <sup>2</sup>No serious inconsistency: statistical heterogeneity was low.<br/> <sup>3</sup>Downgraded by 1 for serious indirectness: all trials were conducted in South Africa. Given the variation in isoniazid resistance globally it is difficult to generalize this result to all settings.<br/> <sup>4</sup>Downgraded by 2 for serious imprecision: to confidently detect a 25% relative reduction in active TB would require a sample size of nearly 3000 participants. This meta‐analysis is therefore underpowered, and the 95% CI includes both appreciable benefit and no effect.<br/> <sup>5</sup>Downgraded by 2 for serious imprecision: there were few events and the 95% CI includes both appreciable harm and no effect. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006418-sec-0024" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006418-sec-0024"></div> <section id="CD006418-sec-0025"> <h3 class="title" id="CD006418-sec-0025">Description of the condition</h3> <p>Tuberculosis (TB) is an important cause of childhood morbidity and death especially in HIV‐positive children (<a href="./references#CD006418-bbs2-0032" title="KochiA . The global tuberculosis situation and the new strategy of the World Health Organisation. Tubercle1991;72:1‐6. ">Kochi 1991</a>; <a href="./references#CD006418-bbs2-0017" title="DonaldPR . Childhood tuberculosis: out of control?. Current Opinion in Pulmonary Medicine2002;8:178‐82. ">Donald 2002</a>). Infection is caused by <i>Mycobacterium tuberculosis</i> and most commonly results in acute and chronic respiratory disease (<a href="./references#CD006418-bbs2-0019" title="FosterK , AltonH . Chronic lung infection in children. Paediatric Respiratory Reviews2003;4:225‐9. ">Foster 2003</a>). In 1994, the incidence of childhood TB increased in low‐ and middle‐income countries (<a href="./references#CD006418-bbs2-0037" title="NelsonLJ , WellsCD . Global epidemiology of childhood tuberculosis. The International Journal of Tuberculosis and Lung Disease2004;8(5):636‐47. ">Nelson 2004</a>). This resurgence was partly attributed to the coexisting burden of HIV disease (<a href="./references#CD006418-bbs2-0055" title="World Health Organization. Global Tuberculosis Report, 2012. apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf(accessed June 2013). ">WHO 2012</a>), which is most pronounced in sub‐Saharan Africa. At the end of 2012, an estimated 3.3 million children under 15 years of age, were living with HIV (<a href="./references#CD006418-bbs2-0049" title="UNAIDS/WHO . AIDS epidemic update. September. www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/201309_epi_core_en.pdf (accessed 25 November 2013). ">UNAIDS/WHO 2013</a>), and 260,000 new HIV infections in children in low‐ and middle‐income countries were reported the same year (<a href="./references#CD006418-bbs2-0049" title="UNAIDS/WHO . AIDS epidemic update. September. www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/201309_epi_core_en.pdf (accessed 25 November 2013). ">UNAIDS/WHO 2013</a>). The World Health Organization (WHO) estimates that, of the 8.7 million incident cases of TB in 2011, approximately 500,000 occurred in children under 15 years of age (<a href="./references#CD006418-bbs2-0055" title="World Health Organization. Global Tuberculosis Report, 2012. apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf(accessed June 2013). ">WHO 2012</a>). However, the burden of childhood TB disease is not as well documented as in adults, partly because of the difficulty of confirming the diagnosis. </p> <p>Dual infection with TB has an important impact on HIV disease. TB accelerates the progression of HIV disease by increasing viral replication (<a href="./references#CD006418-bbs2-0052" title="WhalenC , HorsburghCR , HomD , LahartC , SimberkoffM , EllnerJ . Accelerated course of human immunodeficiency virus infection after tuberculosis. American Journal of Respiratory and Critical Care Medicine1995;151:129‐35. ">Whalen 1995</a>; <a href="./references#CD006418-bbs2-0021" title="GolettiD , WeismanD , JacksonRW , GrahamNM , VlahovD , KleinRS , et al. Effect of mycobacterium tuberculosis on HIV replication: role of immune activation. Journal of Immunology1996;157:1271‐8. ">Goletti 1996</a>). TB is a common cause of acute pneumonia in African HIV‐positive children (<a href="./references#CD006418-bbs2-0058" title="ZarHJ , MansloD , TannebaumE , KleinM , ArgentA , EleyB , et al. Aetiology and outcome of pneumonia in human immunodeficiency virus‐infected children hospitalized in South Africa. Acta Paediatrica2001;90(2):119‐25. ">Zar 2001</a>; <a href="./references#CD006418-bbs2-0031" title="JeenaPM , PillayP , PillayT , CoovadiaHM . Impact of HIV‐1 co‐infection on presentation and hospital‐related mortality in children with culture proven pulmonary tuberculosis in Durban, South Africa. The International Journal of Tuberculosis and Lung Disease2002;6:672‐8. ">Jeena 2002</a>), and may lead to chronic lung disease, including bronchiectasis (<a href="./references#CD006418-bbs2-0029" title="IkeoguMo , WolfB , MatheS . Pulmonary manifestations in HIV seropositivity and malnutrition in Zimbabwe. Archives of Disease in Childhood1997;76:124–8. ">Ikeogu 1997</a>; <a href="./references#CD006418-bbs2-0030" title="JeenaPM , CoovadiaHM , ThulaSA , BlytheD , BuckelsNJ , ChettyR . Persistent and chronic lung disease in HIV‐1‐infected and uninfected African children. AIDS1998;12:1185‐93. ">Jeena 1998</a>). TB is a common cause of death in HIV‐positive children (<a href="./references#CD006418-bbs2-0029" title="IkeoguMo , WolfB , MatheS . Pulmonary manifestations in HIV seropositivity and malnutrition in Zimbabwe. Archives of Disease in Childhood1997;76:124–8. ">Ikeogu 1997</a>; <a href="./references#CD006418-bbs2-0013" title="ChintuC , MwabaP . Tuberculosis in children with human immunodeficiency virus infection. The International Journal of Tuberculosis Lung Disease2005;9(5):477‐84. ">Chintu 2005</a>). Antimycobacterial drugs, such as rifampicin, have deleterious drug interactions with antiretroviral therapy (ART), complicating treatment. Rifampicin, an inducer of cytochrome P450 CYP3A, decreases the concentration of both the protease inhibitors and non‐nucleoside reverse transcriptase inhibitors, leading to sub‐therapeutic levels, and increasing the risk for inadequate viral suppression and consequent drug resistance (<a href="./references#CD006418-bbs2-0042" title="RenY , NuttallJJ , EgbersC , EleyBS , MeyersTM , SmithPJ , et al. Effect of rifampicin on lopinavir pharmacokinetics in HIV‐infected children with tuberculosis. Journal of Acquired Immune Deficiency Syndromes2008;47:566–9. ">Ren 2008</a>; <a href="./references#CD006418-bbs2-0043" title="RenY , NuttallJJ , EgbersC , EleyBS , MeyersTM , SmithPJ , et al. Effect of rifampicin on efavirenz pharmacokinetics in HIV‐infected children with tuberculosis. Journal of Acquired Immune Deficiency Syndromes2009;50:439–43. ">Ren 2009</a>). The large pill burden of two multiple drug regimens increases the risk of adverse events, such as liver toxicity and the likelihood of poorer adherence (<a href="./references#CD006418-bbs2-0012" title="BurmanWJ . Issues in the management of HIV‐related tuberculosis. Clinics in Chest Medicine2005;26:283‐94. ">Burman 2005</a>). </p> <p>Conversely, HIV infection has an impact on TB disease. HIV‐positive children have a higher risk of developing primary TB than HIV‐negative children (<a href="./references#CD006418-bbs2-0035" title="MukadiYD , WiktorZ , CoulibalyIM , CoulibalyD , MbengueA , FolquetAM , et al. Impact of HIV infection on the development, clinical presentation and outcome of tuberculosis among children in Abidjan, Cote d'Ivoire. AIDS1997;11(9):1151‐8. ">Mukadi 1997</a>; <a href="./references#CD006418-bbs2-0027" title="HesselingAC , CottonMF , JenningsT , WhitelawA , JohnsonLF , EleyB , et al. High incidence of tuberculosis among HIV‐infected infants: evidence from a South African population‐based study highlights the need for improved tuberculosis control strategies. Clinical Infectious Diseases2009;48:108–14. ">Hesseling 2009</a>). The diagnosis of TB is more difficult in HIV‐positive children, as other infections or HIV disease may mimic TB. Furthermore, tuberculin skin testing is less sensitive due to immunosuppression, and chest radiography is less specific (<a href="./references#CD006418-bbs2-0011" title="Berggren PalmeI , GudettaB , BruchfieldJ , MuheL , GieseckeJ . Impact of human immunodeficiency virus 1 infection on clinical presentation, treatment outcome and survival in a cohort of Ethiopian children with tuberculosis. Pediatric Infectious Disease Journal2002;21:1053‐61. ">Berggren Palme 2002</a>; <a href="./references#CD006418-bbs2-0013" title="ChintuC , MwabaP . Tuberculosis in children with human immunodeficiency virus infection. The International Journal of Tuberculosis Lung Disease2005;9(5):477‐84. ">Chintu 2005</a>). The outcome of HIV‐positive versus HIV‐negative children with TB co‐infection is poorer, with six‐fold increased death in HIV‐positive children not on ART (<a href="./references#CD006418-bbs2-0011" title="Berggren PalmeI , GudettaB , BruchfieldJ , MuheL , GieseckeJ . Impact of human immunodeficiency virus 1 infection on clinical presentation, treatment outcome and survival in a cohort of Ethiopian children with tuberculosis. Pediatric Infectious Disease Journal2002;21:1053‐61. ">Berggren Palme 2002</a>; <a href="./references#CD006418-bbs2-0026" title="HesselingAC , WestraAE , WerschkullH , DonaldPR , BeyersN , HusseyGD , et al. Outcome of HIV infected children with culture confirmed tuberculosis. Archives of Disease in Childhood2005;90:1171‐4. ">Hesseling 2005</a>). The cure rate of TB in HIV‐positive children not on ART is significantly lower than in HIV‐negative children (<a href="./references#CD006418-bbs2-0035" title="MukadiYD , WiktorZ , CoulibalyIM , CoulibalyD , MbengueA , FolquetAM , et al. Impact of HIV infection on the development, clinical presentation and outcome of tuberculosis among children in Abidjan, Cote d'Ivoire. AIDS1997;11(9):1151‐8. ">Mukadi 1997</a>; <a href="./references#CD006418-bbs2-0011" title="Berggren PalmeI , GudettaB , BruchfieldJ , MuheL , GieseckeJ . Impact of human immunodeficiency virus 1 infection on clinical presentation, treatment outcome and survival in a cohort of Ethiopian children with tuberculosis. Pediatric Infectious Disease Journal2002;21:1053‐61. ">Berggren Palme 2002</a>), with a higher rate of recurrence (<a href="./references#CD006418-bbs2-0046" title="SchaafHS , KrookS , HollemansDW , WarrenRM , DonaldPR , HesselingAC . Recurrent culture‐confirmed tuberculosis in human immunodeficiency virus‐infected children. Pediatric Infectious Disease Journal2005;24(8):685‐91. ">Schaaf 2005</a>). HIV‐positive children may therefore require a longer course of TB treatment (<a href="./references#CD006418-bbs2-0039" title="PerriensJH , StLouisME , MukadiYB , BrownC , PrignotJ , PouthierF , et al. Pulmonary tuberculosis in HIV‐infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. New England Journal of Medicine1995;332(12):779‐84. ">Perriens 1995</a>; <a href="./references#CD006418-bbs2-0045" title="SchaafHS , GeidenduysA , GieRP , CottonMF . Culture‐positive tuberculosis in human immunodeficiency virus type‐1‐infected children. Pediatric Infectious Disease Journal1998;7:599‐604. ">Schaaf 1998</a>). HIV‐positive children, stable on ART, are less likely to develop TB disease and have a better outcome than those not on ART (<a href="./references#CD006418-bbs2-0051" title="WaltersE , CottonMF , RabieH , SchaafHS , WaltersLO , MaraisBJ . Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on anti‐retroviral therapy. BMC Pediatrics2008;8:1. ">Walters 2008</a>; <a href="./references#CD006418-bbs2-0018" title="EdmondsA , LusiamaJ , NapravnikS , KiteteleF , VanRieA , BehetsF . Anti‐retroviral therapy reduces incident tuberculosis in HIV‐infected children. International Journal of Epidemiology2009;38:1612‐21. ">Edmonds 2009</a>; <a href="./references#CD006418-bbs2-0034" title="MartinsonNA , MoultrieH , vanNiekerkR , BarryG , CoovadiaA , CottonM , et al. HAART and risk of tuberculosis in HIV‐infected South African children: a multi‐site retrospective cohort. International Journal of Tuberculosis and Lung Disease2009;13(7):862–7. ">Martinson 2009</a>). However, the initiation of ART in the setting of TB co‐infection can lead to a paradoxical worsening of TB from the 'immune reconstitution syndrome' (<a href="./references#CD006418-bbs2-0036" title="NaritaM , AshkinD , HollenderES , PitchenikAE . Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. American Journal of Respiratory and Critical Care Medicine1998;158(1):157‐61. ">Narita 1998</a>; <a href="./references#CD006418-bbs2-0040" title="PuthanakitT , OberdorferP , AkarathumN , WannaritP , SirisanthanaT , SirianthanaV . Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus‐infected Thai children. Pediatric Infectious Disease Journal2006;25(1):53‐8. ">Puthanakit 2006</a>; <a href="./references#CD006418-bbs2-0057" title="ZampoliM , KilbornT , EleyB . Tuberculosis during early antiretroviral‐induced immune reconstitution in HIV‐infected children. International Journal of Tuberculosis and Lung Disease2007;11(4):417‐23. ">Zampoli 2007</a>; <a href="./references#CD006418-bbs2-0048" title="SmithK , KuhnL , CoovadiaA , MeyersT , HubCC , ReitzC , et al. Immune reconstitution inflammatory syndrome among HIV infected South African infants initiating antiretroviral therapy. AIDS2009;23(9):1097–107. ">Smith 2009</a>). Moreover, the risk of TB in HIV‐positive children on ART is still higher than that of HIV‐negative children (<a href="./references#CD006418-bbs2-0002" title="MadhiSA , NachmanS , ViolariA , KimS , CottonMF , BobatR , et al. Primary isoniazid prophylaxis against tuberculosis in HIV‐exposed children. New England Journal of Medicine2011;365(1):21‐31. ">Madhi 2011</a>). </p> </section> <section id="CD006418-sec-0026"> <h3 class="title" id="CD006418-sec-0026">Description of the intervention</h3> <p>Isoniazid preventive treatment (IPT) is a secondary prevention strategy, whereby isoniazid prevents progression of latent TB to active TB in those at high‐risk of developing active TB (<a href="./references#CD006418-bbs2-0014" title="CohenT , LipsitchM , WalenskyRP , MurrayM . Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV‐tuberculosis co‐infected populations. Proceeding of the National Academy of Sciences of the United States of America2006;103(18):7042‐7. ">Cohen 2006</a>). The WHO currently recommends that HIV/AIDS programmes include IPT as part of their package of care for HIV‐positive people. Current guidelines recommend six months of IPT for HIV‐positive children aged one year and above, without TB disease, even in the absence of a known TB contact; IPT for up to 3 years of use is recommended in HIV‐positive adolescents or adults (<a href="./references#CD006418-bbs2-0053" title="World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach: 2010 revision. www.who.int/hiv/pub/paediatric/infants2010/en/index.html (accessed 16 November 2015). ">WHO 2010</a>; <a href="./references#CD006418-bbs2-0054" title="World Health Organization. Guidelines for intensified tuberculosis case‐finding and isoniazid preventive therapy for people living with HIV in resource‐constrained settings. www.whqlibdoc.who.int/publications/2011/9789241500708_eng.pdf (accessed 16 November 2015). ">WHO 2011</a>). </p> </section> <section id="CD006418-sec-0027"> <h3 class="title" id="CD006418-sec-0027">How the intervention might work</h3> <p>Preventing TB infection and disease in HIV‐positive children is potentially an important public health intervention. Isoniazid has been used successfully as preventive treatment in HIV‐negative children following TB exposure (<a href="./references#CD006418-bbs2-0047" title="SmiejaMJ , MarchettuCA , CookDJ , SmaillFM . Isoniazid for preventing tuberculosis in non‐HIV infected persons. Cochrane Database of Systematic Reviews1999, Issue 1. [DOI: 10.1002/14651858.CD001363] ">Smieja 1999</a>), and in HIV‐infected adults with a positive tuberculin skin test (<a href="./references#CD006418-bbs2-0010" title="AkoloC , AdetifaI , ShepperdS , VolminkJ . Treatment of latent infection in HIV infected persons. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000171.pub3] ">Akolo 2010</a>), where treatment reduced TB disease by 62%.This benefit was found for all preventive drug regimens: isoniazid alone, isoniazid with rifampicin, rifampicin with pyrazinamide and isoniazid, rifampicin and pyrazinamide. No reduction in death was found. Isoniazid offers a further 40% reduction in active TB among HIV‐positive adults on ART (<a href="./references#CD006418-bbs2-0041" title="RangakaMX , WilkinsonRJ , BoulleA , GlynnJR , FieldingK , vanCutsemG , et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis:a randomised double‐blind, placebo‐controlled trial. Lancet2014;384(9944):682‐90. ">Rangaka 2014</a>). Studies showed that IPT reduces active TB at the community and population level (<a href="./references#CD006418-bbs2-0023" title="GrantAD , CharalambousS , FieldingKL , DayJH , CorberttEL , ChaissonRE , et al. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV‐infected men in South Africa. JAMA2005;293(22):2719‐25. ">Grant 2005</a> ). However, the strategy may be compromised by low adherence over the many months necessary to complete a single course of IPT, a problem worsened in HIV‐TB co‐infected individuals for whom IPT durations are prolonged. In contrast to adults, preventive treatment in children is aimed at preventing primary infection rather than reactivation of disease (<a href="./references#CD006418-bbs2-0054" title="World Health Organization. Guidelines for intensified tuberculosis case‐finding and isoniazid preventive therapy for people living with HIV in resource‐constrained settings. www.whqlibdoc.who.int/publications/2011/9789241500708_eng.pdf (accessed 16 November 2015). ">WHO 2011</a>). In settings of high TB prevalence, the rate of TB re‐infection is high (<a href="./references#CD006418-bbs2-0050" title="VerverS , WarrenRM , BeyersN , RichardsonM , van derSpuyGD , BorgdorffMW , et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. American Journal of Respiratory and Critical Care Medicine2005;171:1430–5. ">Verver 2005</a>), and short‐course prophylaxis is potentially inadequate. Longer‐term prophylaxis or repeat courses may be necessary. Preventive treatment can lead to adverse events, mostly liver toxicity, although this is uncommon and rarely requires cessation of antimycobacterial medication in HIV‐positive children (<a href="./references#CD006418-bbs2-0024" title="GrayD , NuttallJ , LombardC , DaviesMA , WorkmanL , ApollesP , et al. Low rates of hepatotoxicity in HIV‐infected children on anti‐retroviral therapy with and without isoniazid prophylaxis. Journal of Tropical Pediatrics2010;56(3):159‐65. ">Gray 2009a</a>; <a href="./references#CD006418-bbs2-0016" title="DonaldPR . Childhood tuberculosis. Current Opinion in Pulmonary Medicine2000;6:187‐92. ">Donald 2000</a>; <a href="./references#CD006418-bbs2-0024" title="GrayD , NuttallJ , LombardC , DaviesMA , WorkmanL , ApollesP , et al. Low rates of hepatotoxicity in HIV‐infected children on anti‐retroviral therapy with and without isoniazid prophylaxis. Journal of Tropical Pediatrics2010;56(3):159‐65. ">Gray 2009a</a>; <a href="./references#CD006418-bbs2-0008" title="leRouxSM , CottonMF , MyerL , leRouxDM , SchaafHS , LombardCJ , et al. Safety of long‐term isoniazid preventive therapy in children with HIV: a comparison of two dosing schedules. International Journal of Tuberculosis and Lung Disease2013;17(1):26‐31. ">Le Roux 2013</a>).The benefits of isoniazid outweigh the risk of liver damage for HIV‐infected people (<a href="./references#CD006418-bbs2-0020" title="GetahunH , GranichR , SculierD , GunnebergC , BlancL , NunnP , et al. Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS2010;24(5):S57‐65. ">Getahun 2010</a>). </p> </section> <section id="CD006418-sec-0028"> <h3 class="title" id="CD006418-sec-0028">Why it is important to do this review</h3> <p>In high‐TB prevalence areas, TB preventive treatment may be effective in preventing infection and development of disease in HIV‐positive children. The efficacy of preventive treatment may, however, be limited by adherence difficulties, adverse events, and cost implications. The true efficacy of TB preventive treatment in HIV‐positive children must be clearly established and balanced against the occurrence of these events. We decided to undertake a Cochrane Review on the efficacy and safety of TB preventive treatment in HIV‐positive children with prophylaxis started in all children diagnosed with HIV infection. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006418-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006418-sec-0029"></div> <p>To summarise the effects of TB preventive treatment versus placebo in HIV‐positive children with no known TB contact on active TB, death, and reported adverse events. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006418-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006418-sec-0030"></div> <section id="CD006418-sec-0031"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006418-sec-0032"> <h4 class="title">Types of studies</h4> <p>We included randomized controlled trials (RCTs) that evaluated the efficacy of TB preventive treatment in participants randomly allocated to preventive treatment for TB and placebo. </p> </section> <section id="CD006418-sec-0033"> <h4 class="title">Types of participants</h4> <p>We included HIV‐positive children, below 13 years, without TB disease currently (irrespective of prior history of TB treatment, infection or prophylaxis). We included children on antiretroviral therapy (ART). For studies that included eligible and non‐eligible participants, we included only effect estimates of eligible participants. </p> </section> <section id="CD006418-sec-0034"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD006418-list-0001"> <li> <p>Intervention group: any TB drug or drug combination.</p> </li> <li> <p>Comparison group: inactive placebo.</p> </li> </ul> </p> <p>We did not impose any restrictions on study interventions, such as dose, duration of treatment, timing of outcome measurement, or co‐interventions. </p> </section> <section id="CD006418-sec-0035"> <h4 class="title">Types of outcome measures</h4> <section id="CD006418-sec-0036"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD006418-list-0002"> <li> <p>Active TB</p> </li> </ul> </p> <p>We defined definite TB by a microbiological or histological identification of <i>Mycobacterium tuberculosis.</i> We based the diagnosis of probable TB on a combination of typical clinical symptoms and signs, tuberculin skin testing, chest radiography, a history of close TB contact, and a documented response to antimycobacterial treatment. </p> </section> <section id="CD006418-sec-0037"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD006418-list-0003"> <li> <p>Death</p> </li> <li> <p>Grade 3 or higher clinical adverse events</p> <ul id="CD006418-list-0004"> <li> <p>Peripheral neuropathy (defined as sensory alteration or paraesthesia causing inability to perform usual social and functional activities or disabling sensory alteration or paraesthesia causing inability to perform age appropriate basic self‐care functions) (<a href="./references#CD006418-bbs2-0038" title="U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division ofAIDS . Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, 2014. https://rsc.tech‐res.com/docs/default‐source/safety/daids_ae_grading_table_v2_nov2014.pdf?sfvrsn=8 (accessed 03 July 2017). ">NIAID 2014</a>) </p> </li> <li> <p>Other clinical adverse events</p> </li> </ul> </li> </ul> <ul id="CD006418-list-0005"> <li> <p>Grade 3 or higher laboratory adverse events</p> <ul id="CD006418-list-0006"> <li> <p>Haematological abnormalities (defined as neutrophil count of 500/mm<sup>3</sup> to 749/mm<sup>3</sup> or &lt; 500/mm<sup>3</sup>; platelet count of 25,000 to 49,999/mm<sup>3</sup> or &lt; 25,000/mm<sup>3</sup>; haemoglobin of 6.5 g/dL to 7.5 g/dL or &lt; 6.5 g/dL) (<a href="./references#CD006418-bbs2-0038" title="U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division ofAIDS . Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, 2014. https://rsc.tech‐res.com/docs/default‐source/safety/daids_ae_grading_table_v2_nov2014.pdf?sfvrsn=8 (accessed 03 July 2017). ">NIAID 2014</a>) </p> </li> </ul> </li> </ul> <ul class="plain" id="CD006418-list-0007"> <li> <ul id="CD006418-list-0008"> <li> <p>Liver enzyme abnormalities (raised alanine aminotransferase and aspartate aminotransferase of 5.1 to 10 or &gt; 10, the upper limit of normal) (<a href="./references#CD006418-bbs2-0038" title="U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division ofAIDS . Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, 2014. https://rsc.tech‐res.com/docs/default‐source/safety/daids_ae_grading_table_v2_nov2014.pdf?sfvrsn=8 (accessed 03 July 2017). ">NIAID 2014</a>) </p> </li> <li> <p>Other laboratory adverse events</p> </li> </ul> </li> </ul> </p> <p>We graded adverse events according to the standardized paediatric AIDS clinical trial grading system of severity of adverse events (<a href="./references#CD006418-bbs2-0038" title="U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division ofAIDS . Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, 2014. https://rsc.tech‐res.com/docs/default‐source/safety/daids_ae_grading_table_v2_nov2014.pdf?sfvrsn=8 (accessed 03 July 2017). ">NIAID 2014</a>). </p> </section> </section> </section> <section id="CD006418-sec-0038"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD006418-sec-0039"> <h4 class="title">Electronic searches</h4> <p>We searched:</p> <p> <ul id="CD006418-list-0009"> <li> <p>MEDLINE/PubMed (1946 to 17 February 2017) <a href="./appendices#CD006418-sec-0090">Appendix 1</a>; </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), in the Cochrane Library (17 February 2017) <a href="./appendices#CD006418-sec-0091">Appendix 2</a>; and </p> </li> <li> <p>Embase (1974 to 17 February 2017) <a href="./appendices#CD006418-sec-0092">Appendix 3</a>. </p> </li> </ul> </p> <p>We also searched for ongoing RCTs of chemoprophylaxis in HIV‐positive children in:</p> <p> <ul id="CD006418-list-0010"> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp</a>; to 17 February 2017); and </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>; to 17 February 2017). </p> </li> </ul> </p> </section> <section id="CD006418-sec-0040"> <h4 class="title">Searching other resources</h4> <p>We handsearched reference lists of identified articles and review articles. We screened abstracts and proceedings of the International Union Against Tuberculosis and Lung Disease (IUATLD) World Congress, the American Thoracic Society International Congress, and the European Respiratory Society World Congress conferences. We contacted investigators of identified trials and other content experts to locate information on any further trials that may not have been included in the electronic databases or presented at conferences, to find out whether these were completed, ongoing, or published. We scrutinized non‐Cochrane reviews for any additional relevant studies or unpublished data. </p> </section> </section> <section id="CD006418-sec-0041"> <h3 class="title" id="CD006418-sec-0041">Data collection and analysis</h3> <section id="CD006418-sec-0042"> <h4 class="title">Selection of studies</h4> <p>MZ and TY scrutinized studies independently for eligibility. We retrieved the full text of relevant articles and independently examined them for eligibility. We included studies if they met the prespecified eligibility criteria. Authors assessing study eligibility were not blinded to the names of the trial investigators, their institutions, journals of publication or results of study. Reasons for excluding studies are summarized in <a href="./references#CD006418-sec-0103" title="">Characteristics of excluded studies</a>. We record the selection process in sufficient detail to complete a PRISMA flow diagram <a href="./references#CD006418-bbs2-0033" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ2009;339:b2700. ">Liberati 2009</a>. </p> </section> <section id="CD006418-sec-0043"> <h4 class="title">Data extraction and management</h4> <p>MZ and a research assistant (OA) extracted the data. The following study characteristics and outcomes were independently extracted in duplicate, under the following subheadings: </p> <p> <ul id="CD006418-list-0011"> <li> <p>Methods (study design, study duration, methodological quality).</p> </li> <li> <p>Participants (inclusion and exclusion criteria, number of patients randomized, setting).</p> </li> <li> <p>Interventions (allocated treatment and dosage regimen, treatment duration)</p> </li> <li> <p>Outcomes (active TB, death, clinical and laboratory adverse events).</p> </li> <li> <p>Study results (number of participants with event of interest and the total number in that study arm for dichotomous outcomes; number lost to follow‐up, and how incomplete data were addressed) </p> </li> </ul> </p> <p>Review authors who authored an included study did not participate in data extraction and assessment of risk of bias of included studies to maintain independence of the review. We summarized data in the <a href="./references#CD006418-sec-0102" title="">Characteristics of included studies</a> tables. </p> </section> <section id="CD006418-sec-0044"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used Cochrane's 'Risk of bias' tool to assess the included studies (<a href="./references#CD006418-bbs2-0015" title="DeeksJ , HigginsJP , AltmanD . Chapter 9: Analysing data and undertaking meta‐analysis. In: HigginsJP , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Chichester (UK): John Wiley &amp; Sons, 2008:243‐96. ">Deeks 2008</a>; <a href="./references#CD006418-bbs2-0028" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). MZ and OA independently assessed the methodological quality of the included studies. We assessed the following domains. </p> <p> <ul id="CD006418-list-0012"> <li> <p>The adequacy of generation of allocation sequence and allocation concealment in preventing selection bias. </p> </li> <li> <p>The presence or absence of blinding of the participant and personnel to reduce performance bias. </p> </li> <li> <p>The method of outcome assessment: whether the same method of assessment was used in both groups and presence or absence of blinding of outcome assessor in the prevention of detection bias. </p> </li> <li> <p>Attrition bias by looking at the percentage of participants included in final analyses and the description of those not included. We also assessed whether or not an intention‐to‐treat analysis was performed. </p> </li> <li> <p>We compared protocols of included studies with published articles to assess for risk of selective reporting bias. </p> </li> <li> <p>Other bias.</p> </li> </ul> </p> <p>We assigned the following judgements for risk of bias for each domain: low risk, high risk, and unclear risk of bias. We resolved disagreements on eligibility and methodological quality of trials by discussion and by obtaining further information from trial authors. We summarized data in a 'Risk of bias' table and graph, which shows our judgements on risk of bias in each domain, for each study separately, and as a percentage across all included studies. </p> </section> <section id="CD006418-sec-0045"> <h4 class="title">Measures of treatment effect</h4> <p>For binary outcomes, we calculated risk ratios (RRs) and associated 95% confidence intervals (CIs). We assessed the effect of the intervention (isoniazid prophylaxis) compared to control (placebo) on the time to event (death and developing TB) with the hazard and incidence rate ratios (95% CI) presented in study reports. </p> </section> <section id="CD006418-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>Two included trials used an intention‐to‐treat analysis to address missing data from participant dropout and the attrition rate was low in the third trial. We contacted the primary author of one included study for missing summary statistics, however, the author did not respond. </p> </section> <section id="CD006418-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the Chi<sup>2</sup> test and I<sup>2</sup> statistic to assess statistical heterogeneity (<a href="./references#CD006418-bbs2-0015" title="DeeksJ , HigginsJP , AltmanD . Chapter 9: Analysing data and undertaking meta‐analysis. In: HigginsJP , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Chichester (UK): John Wiley &amp; Sons, 2008:243‐96. ">Deeks 2008</a>). We considered statistical heterogeneity to be substantial when the Chi<sup>2</sup> test, which assesses if the observed differences in results are due to chance alone, had a P value of &lt; 0.10 and when the I<sup>2</sup> statistic, describing the percentage of variability in effect estimates due to heterogeneity, was &gt; 50%. </p> </section> <section id="CD006418-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>There were too few studies to enable investigation of publication bias using funnel plots. </p> <p><b>Unit of analysis issues</b> </p> <p>All included trials followed a simple parallel group design, where children were individually randomized to either isoniazid prophylaxis or placebo group and a single measurement for each outcome (i.e. active TB or death) was collected and analyzed. </p> </section> <section id="CD006418-sec-0049"> <h4 class="title">Data synthesis</h4> <p>We used a fixed‐effect meta‐analysis incorporating the Mantel‐Haenszel method for dichotomous outcomes and the inverse‐variance method for time‐to‐event outcomes to pool results across studies with no significant heterogeneity (<a href="./references#CD006418-bbs2-0015" title="DeeksJ , HigginsJP , AltmanD . Chapter 9: Analysing data and undertaking meta‐analysis. In: HigginsJP , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Chichester (UK): John Wiley &amp; Sons, 2008:243‐96. ">Deeks 2008</a>). Where meta‐analysis was inappropriate, we reported individual study results separately. We used Review Manager 5 for analysis (<a href="./references#CD006418-bbs2-0044" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). We stratified the analysis by whether the children were receiving ART or not. </p> <section id="CD006418-sec-0050"> <h5 class="title">Assessment of overall certainty of evidence</h5> <p>We used GRADE methodology to assess the overall certainty of evidence (<a href="./references#CD006418-bbs2-0025" title="GuyattGH , OxmanAD , VistG , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. ">Guyatt 2008</a>). In evaluating the certainty of RCT evidence, we considered the following in whether to downgrade the certainty of evidence: methodological limitations, unexplained heterogeneity or inconsistency of study results, indirectness of evidence, imprecision of results, and risk for publication bias. We rated the certainty across studies as high, moderate, low, or very low. </p> <p>We used GRADEpro software to create two 'Summary of findings' tables for the comparisons 'isoniazid prophylaxis compared to placebo for HIV‐positive children not on ART' and 'isoniazid prophylaxis compared to placebo for HIV‐positive children on ART' (<a href="./references#CD006418-bbs2-0022" title="GRADE Working Group, McMaster University. GRADEpro GDT. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro GDT 2014</a>). We included active TB and death outcomes in the 'Summary of findings' tables. </p> <p>MZ and OA independently assessed the certainty of the evidence. We resolved disagreements on certainty ratings by discussion and provided justification for decisions to down‐ or upgrade the ratings using footnotes in the ‘Summary of findings’ table and made comments to aid readers' understanding of the review, where necessary. We used plain language statements to report these findings in the review. </p> </section> </section> <section id="CD006418-sec-0051"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We considered a subgroup analysis based on background TB prevalence, but all studies were from high TB prevalence settings. We will consider subgroup analysis by background TB prevalence in subsequent review updates. </p> <p><b>Sensitivity analysis</b> </p> <p>We could not perform sensitivity analysis due to limited number of trials included in the review. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006418-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006418-sec-0052"></div> <section id="CD006418-sec-0053"> <h3 class="title">Description of studies</h3> <section id="CD006418-sec-0054"> <h4 class="title">Results of the search</h4> <p>In the updated search (17 February 2017) we identified an additional two RCTs with 714 participants. We found no ongoing studies in the updated search (<a href="#CD006418-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD006418-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD006418-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_n/nCD006418-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD006418-sec-0055"> <h4 class="title">Included studies</h4> <section id="CD006418-sec-0056"> <h5 class="title">Design</h5> <p>We included three randomized controlled trials (RCTs) with a total of 991 participants in the review (<a href="./references#CD006418-sec-0102" title="">Characteristics of included studies</a>). Two trials were conducted in South Africa (<a href="./references#CD006418-bbs2-0001" title="GrayDM , WorkmanLJ , LombardCJ , JenningsT , InnesS , GrobbelaarCJ , et al. Isoniazid preventive therapy in HIV infected children on antiretroviral therapy: a pilot study. International Journal of Tuberculosis and Lung Disease2014;18(3):322‐7. ">Gray 2014</a>; <a href="./references#CD006418-bbs2-0003" title="ZarHJ , CottonMF , StraussS , KarpakisJ , HusseyG , SchaafHS , et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Lancet2007;334:136‐42. ">Zar 2007</a>), and one was a multicentre trial that was conducted in South Africa and Botswana; however, enrolment in Botswana began shortly before the study was terminated (<a href="./references#CD006418-bbs2-0002" title="MadhiSA , NachmanS , ViolariA , KimS , CottonMF , BobatR , et al. Primary isoniazid prophylaxis against tuberculosis in HIV‐exposed children. New England Journal of Medicine2011;365(1):21‐31. ">Madhi 2011</a>). </p> </section> <section id="CD006418-sec-0057"> <h5 class="title">Participants</h5> <p>HIV‐positive children in <a href="./references#CD006418-bbs2-0003" title="ZarHJ , CottonMF , StraussS , KarpakisJ , HusseyG , SchaafHS , et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Lancet2007;334:136‐42. ">Zar 2007</a> and <a href="./references#CD006418-bbs2-0001" title="GrayDM , WorkmanLJ , LombardCJ , JenningsT , InnesS , GrobbelaarCJ , et al. Isoniazid preventive therapy in HIV infected children on antiretroviral therapy: a pilot study. International Journal of Tuberculosis and Lung Disease2014;18(3):322‐7. ">Gray 2014</a> were older (median age 24.7 to 38 months) than those in <a href="./references#CD006418-bbs2-0002" title="MadhiSA , NachmanS , ViolariA , KimS , CottonMF , BobatR , et al. Primary isoniazid prophylaxis against tuberculosis in HIV‐exposed children. New England Journal of Medicine2011;365(1):21‐31. ">Madhi 2011</a> (median age 3.2 months). <a href="./references#CD006418-bbs2-0003" title="ZarHJ , CottonMF , StraussS , KarpakisJ , HusseyG , SchaafHS , et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Lancet2007;334:136‐42. ">Zar 2007</a> and <a href="./references#CD006418-bbs2-0001" title="GrayDM , WorkmanLJ , LombardCJ , JenningsT , InnesS , GrobbelaarCJ , et al. Isoniazid preventive therapy in HIV infected children on antiretroviral therapy: a pilot study. International Journal of Tuberculosis and Lung Disease2014;18(3):322‐7. ">Gray 2014</a> included children who had a previous history of TB treatment or prophylaxis, 16% and 12%, respectively, compared to <a href="./references#CD006418-bbs2-0002" title="MadhiSA , NachmanS , ViolariA , KimS , CottonMF , BobatR , et al. Primary isoniazid prophylaxis against tuberculosis in HIV‐exposed children. New England Journal of Medicine2011;365(1):21‐31. ">Madhi 2011</a>, that excluded all children who had a history of TB or known exposure to a microbiologically confirmed case of TB. Compared to <a href="./references#CD006418-bbs2-0002" title="MadhiSA , NachmanS , ViolariA , KimS , CottonMF , BobatR , et al. Primary isoniazid prophylaxis against tuberculosis in HIV‐exposed children. New England Journal of Medicine2011;365(1):21‐31. ">Madhi 2011</a> and <a href="./references#CD006418-bbs2-0001" title="GrayDM , WorkmanLJ , LombardCJ , JenningsT , InnesS , GrobbelaarCJ , et al. Isoniazid preventive therapy in HIV infected children on antiretroviral therapy: a pilot study. International Journal of Tuberculosis and Lung Disease2014;18(3):322‐7. ">Gray 2014</a>, children in <a href="./references#CD006418-bbs2-0003" title="ZarHJ , CottonMF , StraussS , KarpakisJ , HusseyG , SchaafHS , et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Lancet2007;334:136‐42. ">Zar 2007</a> were severely malnourished at enrolment: median weight‐for‐age z‐score −0.88 versus ‐1.56. Children in <a href="./references#CD006418-bbs2-0003" title="ZarHJ , CottonMF , StraussS , KarpakisJ , HusseyG , SchaafHS , et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Lancet2007;334:136‐42. ">Zar 2007</a> (88% with a Centers for Disease Control and Prevention (CDC) category B or C) and <a href="./references#CD006418-bbs2-0001" title="GrayDM , WorkmanLJ , LombardCJ , JenningsT , InnesS , GrobbelaarCJ , et al. Isoniazid preventive therapy in HIV infected children on antiretroviral therapy: a pilot study. International Journal of Tuberculosis and Lung Disease2014;18(3):322‐7. ">Gray 2014</a> (92% with World Health Organization (WHO) classification Stage 3 or 4) were more likely to be severely immuno‐compromised compared to children in <a href="./references#CD006418-bbs2-0002" title="MadhiSA , NachmanS , ViolariA , KimS , CottonMF , BobatR , et al. Primary isoniazid prophylaxis against tuberculosis in HIV‐exposed children. New England Journal of Medicine2011;365(1):21‐31. ">Madhi 2011</a> (8% with a CDC category B or C). </p> <p>Participant inclusion and exclusion criteria are described in the <a href="./references#CD006418-sec-0102" title="">Characteristics of included studies</a> tables. </p> </section> <section id="CD006418-sec-0058"> <h5 class="title">Interventions</h5> <p>Included studies randomly assigned children to isoniazid prophylaxis or placebo group. The dose of isoniazid prophylaxis (10 mg/kg with a variability of 8 mg/kg to 12 mg/kg) and frequency of treatment (either daily or three times weekly) were similar in <a href="./references#CD006418-bbs2-0003" title="ZarHJ , CottonMF , StraussS , KarpakisJ , HusseyG , SchaafHS , et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Lancet2007;334:136‐42. ">Zar 2007</a> and <a href="./references#CD006418-bbs2-0001" title="GrayDM , WorkmanLJ , LombardCJ , JenningsT , InnesS , GrobbelaarCJ , et al. Isoniazid preventive therapy in HIV infected children on antiretroviral therapy: a pilot study. International Journal of Tuberculosis and Lung Disease2014;18(3):322‐7. ">Gray 2014</a> compared to <a href="./references#CD006418-bbs2-0002" title="MadhiSA , NachmanS , ViolariA , KimS , CottonMF , BobatR , et al. Primary isoniazid prophylaxis against tuberculosis in HIV‐exposed children. New England Journal of Medicine2011;365(1):21‐31. ">Madhi 2011</a>, where children received 10 mg/kg to 20 mg/kg of isoniazid daily. Children assigned to the control groups received placebo with identical appearance to isoniazid prophylaxis tablets, and administered in a similar way to isoniazid prophylaxis in the respective studies. </p> <p>In <a href="./references#CD006418-bbs2-0003" title="ZarHJ , CottonMF , StraussS , KarpakisJ , HusseyG , SchaafHS , et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Lancet2007;334:136‐42. ">Zar 2007</a>, ART was initiated in 9% of children at baseline and in 22% during the trial. In <a href="./references#CD006418-bbs2-0002" title="MadhiSA , NachmanS , ViolariA , KimS , CottonMF , BobatR , et al. Primary isoniazid prophylaxis against tuberculosis in HIV‐exposed children. New England Journal of Medicine2011;365(1):21‐31. ">Madhi 2011</a>, ART was initiated at baseline in approximately 20% of HIV‐positive children and in 98.9% within the first year. All children in <a href="./references#CD006418-bbs2-0001" title="GrayDM , WorkmanLJ , LombardCJ , JenningsT , InnesS , GrobbelaarCJ , et al. Isoniazid preventive therapy in HIV infected children on antiretroviral therapy: a pilot study. International Journal of Tuberculosis and Lung Disease2014;18(3):322‐7. ">Gray 2014</a> were on ART. The analysis was stratified as such. In addition, only HIV‐positive children in <a href="./references#CD006418-bbs2-0003" title="ZarHJ , CottonMF , StraussS , KarpakisJ , HusseyG , SchaafHS , et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Lancet2007;334:136‐42. ">Zar 2007</a> and <a href="./references#CD006418-bbs2-0002" title="MadhiSA , NachmanS , ViolariA , KimS , CottonMF , BobatR , et al. Primary isoniazid prophylaxis against tuberculosis in HIV‐exposed children. New England Journal of Medicine2011;365(1):21‐31. ">Madhi 2011</a> received 5 mg/kg of cotrimoxazole. </p> </section> <section id="CD006418-sec-0059"> <h5 class="title">Primary outcome</h5> <p>Active TB was similarly defined across all three trials (see the '<a href="#CD006418-sec-0035">Types of outcome measures</a>' section). </p> </section> </section> <section id="CD006418-sec-0060"> <h4 class="title">Excluded studies</h4> <p>We excluded six studies on review of full articles, see <a href="./references#CD006418-sec-0103" title="">Characteristics of excluded studies</a> tables for details. </p> </section> </section> <section id="CD006418-sec-0061"> <h3 class="title">Risk of bias in included studies</h3> <p>We have presented the risk of bias for each included trial in the 'Risk of bias' table in the '<a href="./references#CD006418-sec-0102" title="">Characteristics of included studies</a>' tables. The 'Risk of bias' summary presents the review authors’ judgements on the risk of bias in each domain, for each trial separately (<a href="#CD006418-fig-0002">Figure 2</a>), while the 'Risk of bias' graph presents the risk of bias in each domain as a percentage across all included trials (<a href="#CD006418-fig-0003">Figure 3</a>). A summary of our findings on study methodological quality for each domain follows below. </p> <div class="figure" id="CD006418-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD006418-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_n/nCD006418-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> </div> <div class="figure" id="CD006418-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD006418-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_n/nCD006418-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD006418-sec-0062"> <h4 class="title">Allocation</h4> <p>Variable block random lists were used by <a href="./references#CD006418-bbs2-0003" title="ZarHJ , CottonMF , StraussS , KarpakisJ , HusseyG , SchaafHS , et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Lancet2007;334:136‐42. ">Zar 2007</a> and <a href="./references#CD006418-bbs2-0001" title="GrayDM , WorkmanLJ , LombardCJ , JenningsT , InnesS , GrobbelaarCJ , et al. Isoniazid preventive therapy in HIV infected children on antiretroviral therapy: a pilot study. International Journal of Tuberculosis and Lung Disease2014;18(3):322‐7. ">Gray 2014</a> for sequence generation; <a href="./references#CD006418-bbs2-0002" title="MadhiSA , NachmanS , ViolariA , KimS , CottonMF , BobatR , et al. Primary isoniazid prophylaxis against tuberculosis in HIV‐exposed children. New England Journal of Medicine2011;365(1):21‐31. ">Madhi 2011</a> created the random list using permuted blocks. Treatment groups were centrally allocated in all three trials (<a href="./references#CD006418-bbs2-0003" title="ZarHJ , CottonMF , StraussS , KarpakisJ , HusseyG , SchaafHS , et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Lancet2007;334:136‐42. ">Zar 2007</a>; <a href="./references#CD006418-bbs2-0002" title="MadhiSA , NachmanS , ViolariA , KimS , CottonMF , BobatR , et al. Primary isoniazid prophylaxis against tuberculosis in HIV‐exposed children. New England Journal of Medicine2011;365(1):21‐31. ">Madhi 2011</a>; <a href="./references#CD006418-bbs2-0001" title="GrayDM , WorkmanLJ , LombardCJ , JenningsT , InnesS , GrobbelaarCJ , et al. Isoniazid preventive therapy in HIV infected children on antiretroviral therapy: a pilot study. International Journal of Tuberculosis and Lung Disease2014;18(3):322‐7. ">Gray 2014</a>). Methods of sequence generation were random and adequate for the three studies (<a href="./references#CD006418-bbs2-0003" title="ZarHJ , CottonMF , StraussS , KarpakisJ , HusseyG , SchaafHS , et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Lancet2007;334:136‐42. ">Zar 2007</a>; <a href="./references#CD006418-bbs2-0002" title="MadhiSA , NachmanS , ViolariA , KimS , CottonMF , BobatR , et al. Primary isoniazid prophylaxis against tuberculosis in HIV‐exposed children. New England Journal of Medicine2011;365(1):21‐31. ">Madhi 2011</a>; <a href="./references#CD006418-bbs2-0001" title="GrayDM , WorkmanLJ , LombardCJ , JenningsT , InnesS , GrobbelaarCJ , et al. Isoniazid preventive therapy in HIV infected children on antiretroviral therapy: a pilot study. International Journal of Tuberculosis and Lung Disease2014;18(3):322‐7. ">Gray 2014</a>). Treatment allocation was adequately concealed in all three trials (<a href="./references#CD006418-bbs2-0003" title="ZarHJ , CottonMF , StraussS , KarpakisJ , HusseyG , SchaafHS , et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Lancet2007;334:136‐42. ">Zar 2007</a>; <a href="./references#CD006418-bbs2-0002" title="MadhiSA , NachmanS , ViolariA , KimS , CottonMF , BobatR , et al. Primary isoniazid prophylaxis against tuberculosis in HIV‐exposed children. New England Journal of Medicine2011;365(1):21‐31. ">Madhi 2011</a>; <a href="./references#CD006418-bbs2-0001" title="GrayDM , WorkmanLJ , LombardCJ , JenningsT , InnesS , GrobbelaarCJ , et al. Isoniazid preventive therapy in HIV infected children on antiretroviral therapy: a pilot study. International Journal of Tuberculosis and Lung Disease2014;18(3):322‐7. ">Gray 2014</a>). </p> </section> <section id="CD006418-sec-0063"> <h4 class="title">Blinding</h4> <p>In <a href="./references#CD006418-bbs2-0003" title="ZarHJ , CottonMF , StraussS , KarpakisJ , HusseyG , SchaafHS , et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Lancet2007;334:136‐42. ">Zar 2007</a>, participants, personnel, and investigators assessing the outcome, including an independent outcome assessor, were blinded to study treatment allocation. Participants, caregivers, investigators, and end point review committee were unaware of study group assignment in <a href="./references#CD006418-bbs2-0002" title="MadhiSA , NachmanS , ViolariA , KimS , CottonMF , BobatR , et al. Primary isoniazid prophylaxis against tuberculosis in HIV‐exposed children. New England Journal of Medicine2011;365(1):21‐31. ">Madhi 2011</a>. Participants and personnel were blinded in <a href="./references#CD006418-bbs2-0001" title="GrayDM , WorkmanLJ , LombardCJ , JenningsT , InnesS , GrobbelaarCJ , et al. Isoniazid preventive therapy in HIV infected children on antiretroviral therapy: a pilot study. International Journal of Tuberculosis and Lung Disease2014;18(3):322‐7. ">Gray 2014</a>. The radiologist and the clinician (outcomes assessors) were blinded to the prophylactic regimen to which the child was allocated (<a href="./references#CD006418-bbs2-0001" title="GrayDM , WorkmanLJ , LombardCJ , JenningsT , InnesS , GrobbelaarCJ , et al. Isoniazid preventive therapy in HIV infected children on antiretroviral therapy: a pilot study. International Journal of Tuberculosis and Lung Disease2014;18(3):322‐7. ">Gray 2014</a>). We assessed the three studies as having low risk of participant and personnel performance bias and detection bias (<a href="./references#CD006418-bbs2-0003" title="ZarHJ , CottonMF , StraussS , KarpakisJ , HusseyG , SchaafHS , et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Lancet2007;334:136‐42. ">Zar 2007</a>; <a href="./references#CD006418-bbs2-0002" title="MadhiSA , NachmanS , ViolariA , KimS , CottonMF , BobatR , et al. Primary isoniazid prophylaxis against tuberculosis in HIV‐exposed children. New England Journal of Medicine2011;365(1):21‐31. ">Madhi 2011</a>; <a href="./references#CD006418-bbs2-0001" title="GrayDM , WorkmanLJ , LombardCJ , JenningsT , InnesS , GrobbelaarCJ , et al. Isoniazid preventive therapy in HIV infected children on antiretroviral therapy: a pilot study. International Journal of Tuberculosis and Lung Disease2014;18(3):322‐7. ">Gray 2014</a>). </p> </section> <section id="CD006418-sec-0064"> <h4 class="title">Incomplete outcome data</h4> <p>The three studies were at low risk of attrition bias, because the attrition rate was below 20% in one study (<a href="./references#CD006418-bbs2-0003" title="ZarHJ , CottonMF , StraussS , KarpakisJ , HusseyG , SchaafHS , et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Lancet2007;334:136‐42. ">Zar 2007</a>), and all participants randomized were included in analysis in two trials (<a href="./references#CD006418-bbs2-0002" title="MadhiSA , NachmanS , ViolariA , KimS , CottonMF , BobatR , et al. Primary isoniazid prophylaxis against tuberculosis in HIV‐exposed children. New England Journal of Medicine2011;365(1):21‐31. ">Madhi 2011</a>; <a href="./references#CD006418-bbs2-0001" title="GrayDM , WorkmanLJ , LombardCJ , JenningsT , InnesS , GrobbelaarCJ , et al. Isoniazid preventive therapy in HIV infected children on antiretroviral therapy: a pilot study. International Journal of Tuberculosis and Lung Disease2014;18(3):322‐7. ">Gray 2014</a>). </p> </section> <section id="CD006418-sec-0065"> <h4 class="title">Selective reporting</h4> <p>We judged risk of reporting bias to be low in all three trials (<a href="./references#CD006418-bbs2-0003" title="ZarHJ , CottonMF , StraussS , KarpakisJ , HusseyG , SchaafHS , et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Lancet2007;334:136‐42. ">Zar 2007</a>; <a href="./references#CD006418-bbs2-0002" title="MadhiSA , NachmanS , ViolariA , KimS , CottonMF , BobatR , et al. Primary isoniazid prophylaxis against tuberculosis in HIV‐exposed children. New England Journal of Medicine2011;365(1):21‐31. ">Madhi 2011</a>; <a href="./references#CD006418-bbs2-0001" title="GrayDM , WorkmanLJ , LombardCJ , JenningsT , InnesS , GrobbelaarCJ , et al. Isoniazid preventive therapy in HIV infected children on antiretroviral therapy: a pilot study. International Journal of Tuberculosis and Lung Disease2014;18(3):322‐7. ">Gray 2014</a>). All outcomes stated in the study protocols were reported in the published manuscripts. </p> </section> <section id="CD006418-sec-0066"> <h4 class="title">Other potential sources of bias</h4> <p>The risk of other bias was unclear in one study; the data safety monitoring board recommended randomization into the placebo group to be stopped after 277 of the planned 432 participants were enrolled (<a href="./references#CD006418-bbs2-0003" title="ZarHJ , CottonMF , StraussS , KarpakisJ , HusseyG , SchaafHS , et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Lancet2007;334:136‐42. ">Zar 2007</a>). Two studies were at low risk of other potential sources of bias (<a href="./references#CD006418-bbs2-0002" title="MadhiSA , NachmanS , ViolariA , KimS , CottonMF , BobatR , et al. Primary isoniazid prophylaxis against tuberculosis in HIV‐exposed children. New England Journal of Medicine2011;365(1):21‐31. ">Madhi 2011</a>; <a href="./references#CD006418-bbs2-0001" title="GrayDM , WorkmanLJ , LombardCJ , JenningsT , InnesS , GrobbelaarCJ , et al. Isoniazid preventive therapy in HIV infected children on antiretroviral therapy: a pilot study. International Journal of Tuberculosis and Lung Disease2014;18(3):322‐7. ">Gray 2014</a>). </p> </section> </section> <section id="CD006418-sec-0067"> <h3 class="title" id="CD006418-sec-0067">Effects of interventions</h3> <p>See: <a href="./full#CD006418-tbl-0001"><b>Summary of findings for the main comparison</b> Isoniazid prophylaxis compared to placebo for HIV‐positive children not on antiretroviral therapy (ART)</a>; <a href="./full#CD006418-tbl-0002"><b>Summary of findings 2</b> Isoniazid prophylaxis compared to placebo for HIV‐positive children on antiretroviral therapy (ART)</a> </p> <section id="CD006418-sec-0068"> <h4 class="title">Isoniazid versus placebo</h4> <section id="CD006418-sec-0069"> <h5 class="title">HIV‐positive children not on antiretroviral therapy (ART)</h5> <section id="CD006418-sec-0070"> <h6 class="title">Active tuberculosis (TB)</h6> <p>One trial from South Africa assessed the effects of isoniazid prophylaxis in HIV‐positive children not taking ART. This trial was stopped early when 263 of 432 (61%) planned participants had been recruited, due to a result that had reached standard levels of statistical significance. Isoniazid prophylaxis reduce the number of children developing active TB by 69% (hazard ratio (HR) 0.31, 95% confidence interval (CI) 0.11 to 0.87; 1 trial, 240 participants, (review authors own figures), <i>low certainty evidence</i>). The number of events in this trial was very low. Therefore, we judged the result to be of low certainty, when downgraded for serious indirectness and imprecision (<a href="./full#CD006418-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD006418-sec-0071"> <h6 class="title">Death</h6> <p>In children not taking ART, isoniazid prophylaxis reduces death by more than 50% (risk ratio (RR) 0.46, 95% CI 0.22 to 0.95; 1 trial, 240 participants, (review authors own figures), <i>low certainty evidence</i>; <a href="./full#CD006418-tbl-0001">summary of findings Table for the main comparison</a>). We downgraded the trial for serious indirectness and imprecision. </p> </section> <section id="CD006418-sec-0072"> <h6 class="title">Clinical adverse events (grade 3 or higher)</h6> <p>One trial (<a href="./references#CD006418-bbs2-0003" title="ZarHJ , CottonMF , StraussS , KarpakisJ , HusseyG , SchaafHS , et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Lancet2007;334:136‐42. ">Zar 2007</a>) reported no clinical adverse events in children not on ART (<a href="#CD006418-tbl-0003">Table 1</a>). </p> <div class="table" id="CD006418-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Number of children with adverse events and number of adverse events (of grade 3 or higher) in HIV‐positive children on antiretroviral therapy (ART) and not on ART, by study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""></td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Number of children with adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Number of adverse events</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD006418-bbs2-0003" title="ZarHJ , CottonMF , StraussS , KarpakisJ , HusseyG , SchaafHS , et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Lancet2007;334:136‐42. ">Zar 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD006418-bbs2-0002" title="MadhiSA , NachmanS , ViolariA , KimS , CottonMF , BobatR , et al. Primary isoniazid prophylaxis against tuberculosis in HIV‐exposed children. New England Journal of Medicine2011;365(1):21‐31. ">Madhi 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD006418-bbs2-0001" title="GrayDM , WorkmanLJ , LombardCJ , JenningsT , InnesS , GrobbelaarCJ , et al. Isoniazid preventive therapy in HIV infected children on antiretroviral therapy: a pilot study. International Journal of Tuberculosis and Lung Disease2014;18(3):322‐7. ">Gray 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Children not on ART</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Children on ART</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Children on ART</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Children on ART</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Isoniazid prophylaxis group</p> <p>N = 91</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo group</p> <p>N = 91</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Isoniazid prophylaxis group</p> <p>N = 41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo group</p> <p>N = 40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Isoniazid prophylaxis group</p> <p>N = 273</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo group</p> <p>N = 274</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Isoniazid prophylaxis group</p> <p>N= 85</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo group</p> <p>N = 82</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Clinical adverse events</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peripheral neuropathy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other clinical adverse events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>Laboratory adverse events</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haematological (neutropenia, thrombocytopenia, anaemia)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver enzyme abnormalities</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other laboratory adverse events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: ART: antiretroviral therapy; N: number of participants.</p> </div> </div> </section> <section id="CD006418-sec-0073"> <h6 class="title">Laboratory adverse events (grade 3 or higher)</h6> <p>One trial (182 participants) reported the number of children not on ART with laboratory adverse events (<a href="./references#CD006418-bbs2-0003" title="ZarHJ , CottonMF , StraussS , KarpakisJ , HusseyG , SchaafHS , et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Lancet2007;334:136‐42. ">Zar 2007</a>) (<a href="#CD006418-tbl-0003">Table 1</a>). Five and six children had haematological abnormalities (RR 0.83, 95% CI 0.26 to 2.63) in the isoniazid prophylaxis and placebo groups, respectively. None of the children in the isoniazid prophylaxis group, but two in the placebo group had liver enzyme abnormalities. </p> </section> </section> <section id="CD006418-sec-0074"> <h5 class="title">HIV‐positive children on antiretroviral therapy (ART)</h5> <section id="CD006418-sec-0075"> <h6 class="title">Active TB</h6> <p>In HIV‐positive children on ART, isoniazid prophylaxis conferred neither benefit nor harm on active TB (RR 0.76, 95% CI 0.50 to 1.14; 3 trials, 737 participants, <i>very low certainty evidence</i>; <a href="./references#CD006418-fig-0006" title="">Analysis 1.1</a>; <a href="#CD006418-fig-0004">Figure 4</a>; <a href="./full#CD006418-tbl-0002">summary of findings Table 2</a>). The trials and the meta‐analysis were underpowered to detect clinically important effects and consequently the 95% CI is wide (<a href="#CD006418-tbl-0004">Table 2</a>). The vast majority of data were from South Africa, limiting the broad generalization of the findings to other settings. </p> <div class="figure" id="CD006418-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Isoniazid prophylaxis versus placebo, outcome: 1.1 Active TB, HIV‐positive children on ART." data-id="CD006418-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_n/nCD006418-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Isoniazid prophylaxis versus placebo, outcome: 1.1 Active TB, HIV‐positive children on ART. </p> </div> </div> </div> <div class="table" id="CD006418-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Optimal information size calculations</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Source</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinically important relative reduction</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sample size required<sup>1,2</sup> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active TB</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46/366 (13%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006418-fig-0006" title="">Analysis 1.1</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2990</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/366 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006418-fig-0007" title="">Analysis 1.2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2282</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>We based all calculations on: 2‐sided tests, with a ratio of 1:1, power of 0.8, and confidence level of 0.05.<br/> <sup>2</sup>We performed all calculations using: <a href="http://www.sealedenvelope.com/power/binary-superiority" target="_blank">sealedenvelope.com/power/binary‐superiority</a> </p> </div> </div> </section> <section id="CD006418-sec-0076"> <h6 class="title">Death</h6> <p>Isoniazid prophylaxis conferred neither benefit nor harm on death (RR 1.45, 95% CI 0.78 to 2.72; 3 trials, 737 participants, <i>very low certainty evidence</i>; <a href="./references#CD006418-fig-0007" title="">Analysis 1.2</a>; <a href="#CD006418-fig-0005">Figure 5</a>; <a href="./full#CD006418-tbl-0002">summary of findings Table 2</a>). The trials were underpowered to detect clinically important effects of isoniazid prophylaxis on death (<a href="#CD006418-tbl-0004">Table 2</a>). We downgraded the trials for indirectness and serious imprecision. </p> <div class="figure" id="CD006418-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Isoniazid prophylaxis versus placebo, outcome: 1.2 Death, HIV‐positive children on ART." data-id="CD006418-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_n/nCD006418-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Isoniazid prophylaxis versus placebo, outcome: 1.2 Death, HIV‐positive children on ART. </p> </div> </div> </div> </section> <section id="CD006418-sec-0077"> <h6 class="title">Clinical adverse events (grade 3 or higher)</h6> <p>Two trials (714 participants) reported number of clinical adverse events (<a href="#CD006418-tbl-0003">Table 1</a>). Three and two peripheral neuropathy abnormalities occurred in the isoniazid prophylaxis and placebo groups, respectively (<a href="./references#CD006418-bbs2-0002" title="MadhiSA , NachmanS , ViolariA , KimS , CottonMF , BobatR , et al. Primary isoniazid prophylaxis against tuberculosis in HIV‐exposed children. New England Journal of Medicine2011;365(1):21‐31. ">Madhi 2011</a>); 15 and 24 other clinical adverse events respectively, occurred in the isoniazid prophylaxis and placebo groups (<a href="./references#CD006418-bbs2-0002" title="MadhiSA , NachmanS , ViolariA , KimS , CottonMF , BobatR , et al. Primary isoniazid prophylaxis against tuberculosis in HIV‐exposed children. New England Journal of Medicine2011;365(1):21‐31. ">Madhi 2011</a>; <a href="./references#CD006418-bbs2-0001" title="GrayDM , WorkmanLJ , LombardCJ , JenningsT , InnesS , GrobbelaarCJ , et al. Isoniazid preventive therapy in HIV infected children on antiretroviral therapy: a pilot study. International Journal of Tuberculosis and Lung Disease2014;18(3):322‐7. ">Gray 2014</a>). </p> <p><b>Laboratory adverse events (grade 3 or higher)</b> </p> <p>Three trials (795 participants) reported number of laboratory adverse events (<a href="#CD006418-tbl-0003">Table 1</a>). There were 10 and 9 haematological abnormalities in the isoniazid prophylaxis and placebo groups (<a href="./references#CD006418-bbs2-0002" title="MadhiSA , NachmanS , ViolariA , KimS , CottonMF , BobatR , et al. Primary isoniazid prophylaxis against tuberculosis in HIV‐exposed children. New England Journal of Medicine2011;365(1):21‐31. ">Madhi 2011</a>); and 15 and 13 liver enzyme abnormalities in the isoniazid prophylaxis and placebo groups, respectively (<a href="./references#CD006418-bbs2-0002" title="MadhiSA , NachmanS , ViolariA , KimS , CottonMF , BobatR , et al. Primary isoniazid prophylaxis against tuberculosis in HIV‐exposed children. New England Journal of Medicine2011;365(1):21‐31. ">Madhi 2011</a>; <a href="./references#CD006418-bbs2-0001" title="GrayDM , WorkmanLJ , LombardCJ , JenningsT , InnesS , GrobbelaarCJ , et al. Isoniazid preventive therapy in HIV infected children on antiretroviral therapy: a pilot study. International Journal of Tuberculosis and Lung Disease2014;18(3):322‐7. ">Gray 2014</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006418-sec-0078" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006418-sec-0078"></div> <section id="CD006418-sec-0079"> <h3 class="title" id="CD006418-sec-0079">Summary of main results</h3> <p>In HIV‐positive children not taking antiretroviral therapy (ART), isoniazid prophylaxis may reduce active TB disease (low certainty evidence), and death (low certainty evidence). In HIV‐positive children without known exposure to a TB source case, and on ART, isoniazid prophylaxis conferred neither benefit nor harm for active TB (very low certainty evidence) or death (very low certainty evidence). HIV treatment may modify the effect of TB preventive treatment. Clinical adverse events were similar between the isoniazid prophylaxis and placebo groups, both in children not on ART and those on ART. Laboratory adverse events were similar between the isoniazid prophylaxis and placebo groups, both in children not on ART and those on ART. In a secondary analysis of <a href="./references#CD006418-bbs2-0003" title="ZarHJ , CottonMF , StraussS , KarpakisJ , HusseyG , SchaafHS , et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Lancet2007;334:136‐42. ">Zar 2007</a> data, <a href="./references#CD006418-bbs2-0008" title="leRouxSM , CottonMF , MyerL , leRouxDM , SchaafHS , LombardCJ , et al. Safety of long‐term isoniazid preventive therapy in children with HIV: a comparison of two dosing schedules. International Journal of Tuberculosis and Lung Disease2013;17(1):26‐31. ">Le Roux 2013</a> showed that 16 (5.4%) out of 297 children developed severe liver injury while receiving isoniazid, but that only 1.7% of these cases were related to isoniazid prophylaxis. </p> </section> <section id="CD006418-sec-0080"> <h3 class="title" id="CD006418-sec-0080">Overall completeness and applicability of evidence</h3> <p>Isoniazid preventive therapy is currently recommended for preventing TB infection in HIV‐positive children. We included three trials (n = 991) in this review, which enrolled both young and older HIV‐positive children, living in areas of high TB prevalence. Most of the data were from South Africa, limiting the generalizability of the review findings to other settings, given the variation in isoniazid resistance globally. The trials were underpowered to detect clinically important effects of isoniazid prophylaxis on active TB and death in HIV‐positive children taking ART. ART is known to protect against TB disease, and adequately powered randomized controlled trials (RCTs) are therefore required to assess the possibility of isoniazid prophylaxis efficacy added to ART. Further data on isoniazid prophylaxis efficacy at varying levels of immunosuppression (HIV disease) are required. </p> </section> <section id="CD006418-sec-0081"> <h3 class="title" id="CD006418-sec-0081">Quality of the evidence</h3> <p>We used the GRADE approach to rate the certainty of the evidence <a href="./references#CD006418-bbs2-0022" title="GRADE Working Group, McMaster University. GRADEpro GDT. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro GDT 2014</a>. In evaluating the certainty of RCT evidence, we considered the following in whether to downgrade the certainty of the evidence: methodological limitations, inconsistency in study results, indirectness, imprecision, and publication bias. We presented the evidence in two 'Summary of findings' tables for isoniazid prophylaxis efficacy; one for HIV‐positive children not on ART (<a href="./full#CD006418-tbl-0001">summary of findings Table for the main comparison</a>), and the other for HIV‐positive children on ART (<a href="./full#CD006418-tbl-0002">summary of findings Table 2</a>). The evidence on the effect of isoniazid prophylaxis for active TB and death in HIV‐positive children not on ART was of low certainty. The effect of isoniazid prophylaxis for active TB and death in HIV‐positive children on ART was inconclusive and the evidence was of very low certainty. We downgraded the trials for serious indirectness and imprecision because all were conducted in one setting and were underpowered with wide confidence intervals. </p> </section> <section id="CD006418-sec-0082"> <h3 class="title" id="CD006418-sec-0082">Potential biases in the review process</h3> <p>We conducted an extensive and comprehensive search of electronic databases, with no language restrictions, to identify published and unpublished trials. MZ and TY independently performed study selection. MZ and OA independently extracted the data and assessed the methodological quality of included studies. Review authors who authored an included study, were not involved in extraction of data and assessment of methodological quality of any included studies, to maintain independence of the review. </p> </section> <section id="CD006418-sec-0083"> <h3 class="title" id="CD006418-sec-0083">Agreements and disagreements with other studies or reviews</h3> <p>The results of this review were similar to those from a review of isoniazid prophylaxis in adults (<a href="./references#CD006418-bbs2-0010" title="AkoloC , AdetifaI , ShepperdS , VolminkJ . Treatment of latent infection in HIV infected persons. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000171.pub3] ">Akolo 2010</a>). Isoniazid prophylaxis had a greater protective effect on TB disease in HIV‐positive children not on ART, reducing the chance of developing active childhood TB disease by 69%, similar to the 62% reduction in risk of active disease, found in the adult review (<a href="./references#CD006418-bbs2-0010" title="AkoloC , AdetifaI , ShepperdS , VolminkJ . Treatment of latent infection in HIV infected persons. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000171.pub3] ">Akolo 2010</a>). Evidence on impact of isoniazid prophylaxis on death in HIV‐positive children not on ART, showed a 54% reduction in death (<a href="./references#CD006418-bbs2-0003" title="ZarHJ , CottonMF , StraussS , KarpakisJ , HusseyG , SchaafHS , et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Lancet2007;334:136‐42. ">Zar 2007</a>). In contrast, isoniazid prophylaxis had no significant effect on TB disease and death in HIV‐positive children on ART; these findings were consistent with the <a href="./references#CD006418-bbs2-0010" title="AkoloC , AdetifaI , ShepperdS , VolminkJ . Treatment of latent infection in HIV infected persons. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD000171.pub3] ">Akolo 2010</a> review in HIV‐positive adults, reporting no effect on death, in a comparison of any drug for TB versus placebo. These findings may be consistent with the protective effect of ART, in reducing the risk of TB disease and death in HIV‐positive children. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006418-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/urn:x-wiley:14651858:media:CD006418:CD006418-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_t/tCD006418-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD006418-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_n/nCD006418-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/full#CD006418-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_n/nCD006418-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006418-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/urn:x-wiley:14651858:media:CD006418:CD006418-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_t/tCD006418-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD006418-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_n/nCD006418-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/full#CD006418-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_n/nCD006418-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006418-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/urn:x-wiley:14651858:media:CD006418:CD006418-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_t/tCD006418-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD006418-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_n/nCD006418-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/full#CD006418-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_n/nCD006418-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006418-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/urn:x-wiley:14651858:media:CD006418:CD006418-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_t/tCD006418-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Isoniazid prophylaxis versus placebo, outcome: 1.1 Active TB, HIV‐positive children on ART." data-id="CD006418-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_n/nCD006418-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Isoniazid prophylaxis versus placebo, outcome: 1.1 Active TB, HIV‐positive children on ART. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/full#CD006418-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_n/nCD006418-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006418-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/urn:x-wiley:14651858:media:CD006418:CD006418-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_t/tCD006418-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Isoniazid prophylaxis versus placebo, outcome: 1.2 Death, HIV‐positive children on ART." data-id="CD006418-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_n/nCD006418-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Isoniazid prophylaxis versus placebo, outcome: 1.2 Death, HIV‐positive children on ART. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/full#CD006418-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_n/nCD006418-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006418-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/urn:x-wiley:14651858:media:CD006418:CD006418-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_t/tCD006418-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Isoniazid prophylaxis versus placebo for HIV‐positive children on antiretroviral therapy (ART), Outcome 1 Active TB." data-id="CD006418-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_n/nCD006418-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Isoniazid prophylaxis versus placebo for HIV‐positive children on antiretroviral therapy (ART), Outcome 1 Active TB. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/references#CD006418-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_n/nCD006418-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006418-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/urn:x-wiley:14651858:media:CD006418:CD006418-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_t/tCD006418-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Isoniazid prophylaxis versus placebo for HIV‐positive children on antiretroviral therapy (ART), Outcome 2 Death." data-id="CD006418-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_n/nCD006418-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Isoniazid prophylaxis versus placebo for HIV‐positive children on antiretroviral therapy (ART), Outcome 2 Death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/references#CD006418-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/media/CDSR/CD006418/image_n/nCD006418-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006418-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Isoniazid prophylaxis compared to placebo for HIV‐positive children not on antiretroviral therapy (ART)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Isoniazid prophylaxis compared to placebo for HIV‐positive children not on antiretroviral therapy (ART)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> HIV‐positive children not taking ART<br/> <b>Settings:</b> any setting<br/> <b>Intervention:</b> isoniazid prophylaxis daily or three times weekly<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comment</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Isoniazid prophylaxis </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active TB</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 100</p> <p>(1 to 9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.31</p> <p>(95% CI 0.11 to 0.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3,4,5</sup> </p> <p>due to serious indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Isoniazid prophylaxis may reduce active TB</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 100</p> <p>(8 per 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.46</p> <p>(95% CI 0.22 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3,4,5</sup> </p> <p>due to serious indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Isoniazid prophylaxis may reduce death</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>HR</b>: hazard ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No serious risk of bias: this trial was at low risk of selection bias, and adequately blinded study participants and personnel. However, the study was stopped early on the recommendation of the data safety monitoring board after only 277 of the planned 432 were enrolled. Not downgraded.<br/> <sup>2</sup>No serious inconsistency: a single trial.<br/> <sup>3</sup>Downgraded by 1 for serious indirectness: this single trial is from a single setting in South Africa. Broad generalization of this result to other settings is difficult given the variation in isoniazid resistance worldwide.<br/> <sup>4</sup>Downgraded by 1 for serious imprecision: there were very few events in this trial and as such the finding is fragile. The original paper reports the result using a hazard ratio and the result reached standard levels of statistical significance.<br/> <sup>5</sup>We reported the study authors' data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Isoniazid prophylaxis compared to placebo for HIV‐positive children not on antiretroviral therapy (ART)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/full#CD006418-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006418-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Isoniazid prophylaxis compared to placebo for HIV‐positive children on antiretroviral therapy (ART)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Isoniazid prophylaxis compared to placebo for HIV‐positive children on antiretroviral therapy (ART)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> HIV‐positive children on ART<br/> <b>Settings:</b> any setting<br/> <b>Intervention:</b> isoniazid prophylaxis daily or three times weekly<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Isoniazid prophylaxis </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Active TB</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 100</b> <br/> (7 to 15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.76</b> <br/> (0.50 to 1.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>737<br/> (3 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3,4</sup> </p> <p>due to serious indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We don't know if Isoniazid prophylaxis reduce active TB</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b> <br/> (3 to 11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.45</b> </p> <p>(0.78 to 2.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>737<br/> (3 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3,5</sup> </p> <p>due to serious indirectness and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We don't know if Isoniazid prophylaxis reduce death</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>No serious risk of bias: trials were at low risk of selection bias. Both studies adequately blinded study participants and personnel.<br/> <sup>2</sup>No serious inconsistency: statistical heterogeneity was low.<br/> <sup>3</sup>Downgraded by 1 for serious indirectness: all trials were conducted in South Africa. Given the variation in isoniazid resistance globally it is difficult to generalize this result to all settings.<br/> <sup>4</sup>Downgraded by 2 for serious imprecision: to confidently detect a 25% relative reduction in active TB would require a sample size of nearly 3000 participants. This meta‐analysis is therefore underpowered, and the 95% CI includes both appreciable benefit and no effect.<br/> <sup>5</sup>Downgraded by 2 for serious imprecision: there were few events and the 95% CI includes both appreciable harm and no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Isoniazid prophylaxis compared to placebo for HIV‐positive children on antiretroviral therapy (ART)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/full#CD006418-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006418-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Number of children with adverse events and number of adverse events (of grade 3 or higher) in HIV‐positive children on antiretroviral therapy (ART) and not on ART, by study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""></td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Number of children with adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Number of adverse events</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD006418-bbs2-0003" title="ZarHJ , CottonMF , StraussS , KarpakisJ , HusseyG , SchaafHS , et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Lancet2007;334:136‐42. ">Zar 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD006418-bbs2-0002" title="MadhiSA , NachmanS , ViolariA , KimS , CottonMF , BobatR , et al. Primary isoniazid prophylaxis against tuberculosis in HIV‐exposed children. New England Journal of Medicine2011;365(1):21‐31. ">Madhi 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD006418-bbs2-0001" title="GrayDM , WorkmanLJ , LombardCJ , JenningsT , InnesS , GrobbelaarCJ , et al. Isoniazid preventive therapy in HIV infected children on antiretroviral therapy: a pilot study. International Journal of Tuberculosis and Lung Disease2014;18(3):322‐7. ">Gray 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Children not on ART</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Children on ART</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Children on ART</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Children on ART</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Isoniazid prophylaxis group</p> <p>N = 91</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo group</p> <p>N = 91</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Isoniazid prophylaxis group</p> <p>N = 41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo group</p> <p>N = 40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Isoniazid prophylaxis group</p> <p>N = 273</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo group</p> <p>N = 274</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Isoniazid prophylaxis group</p> <p>N= 85</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo group</p> <p>N = 82</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Clinical adverse events</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Peripheral neuropathy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other clinical adverse events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>Laboratory adverse events</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haematological (neutropenia, thrombocytopenia, anaemia)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liver enzyme abnormalities</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other laboratory adverse events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>Abbreviations: ART: antiretroviral therapy; N: number of participants.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Number of children with adverse events and number of adverse events (of grade 3 or higher) in HIV‐positive children on antiretroviral therapy (ART) and not on ART, by study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/full#CD006418-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006418-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Optimal information size calculations</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Source</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinically important relative reduction</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sample size required<sup>1,2</sup> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active TB</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46/366 (13%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006418-fig-0006" title="">Analysis 1.1</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2990</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/366 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006418-fig-0007" title="">Analysis 1.2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2282</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup>We based all calculations on: 2‐sided tests, with a ratio of 1:1, power of 0.8, and confidence level of 0.05.<br/> <sup>2</sup>We performed all calculations using: <a href="http://www.sealedenvelope.com/power/binary-superiority" target="_blank">sealedenvelope.com/power/binary‐superiority</a> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Optimal information size calculations</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/full#CD006418-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006418-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Isoniazid prophylaxis versus placebo for HIV‐positive children on antiretroviral therapy (ART)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Active TB <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.50, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.78, 2.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Isoniazid prophylaxis versus placebo for HIV‐positive children on antiretroviral therapy (ART)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006418.pub3/references#CD006418-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006418.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006418-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006418-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD006418-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD006418-note-0009">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006418\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006418\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006418\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006418\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006418\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006418\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006418\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006418\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006418\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006418\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006418\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006418\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006418\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006418\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006418\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006418\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006418\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006418\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QO4KtYGW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006418.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006418.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006418.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006418.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006418.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728049985"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006418.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728049989"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006418.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ebaff694cf498',t:'MTc0MDcyODA1MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 